Avantor Under Pressure as Activist Investor Demands Sale or Major Changes

Activist investor Engine Capital plans to disclose its 3% stake in biotechnology company Avantor (AVTR) on Monday, pushing for major changes or a sale. The investment firm estimates Avantor could fetch $17-$19 per share, compared to its current price of $11.50. Avantor is struggling with weaker demand due to reduced government funding under the Trump administration and has fallen 45% year-to-date.

Activist investor Engine Capital is set to disclose its 3% stake in biotechnology company Avantor (NYSE: AVTR) on Monday, aiming to push for significant changes or a potential sale. The investment firm, which has built up its position in the lab equipment supplier, is expected to advocate for a board refresh, stock buybacks, and the divestiture of non-core assets, according to a Wall Street Journal report [3].

Engine Capital estimates that Avantor could fetch between $17 and $19 per share, a substantial increase from its current price of $11.50. The investment firm's stake in Avantor comes as the company has experienced a 45% year-to-date decline in its stock price, driven by slowing demand in the lab equipment sector, primarily due to reduced government funding under the Trump administration [1].

Avantor reported mixed results for the second quarter of 2025, with GAAP revenue narrowly exceeding analyst expectations but several profitability measures falling short. The company's adjusted EBITDA margin and free cash flow both declined year-over-year, indicating ongoing operational and competitive pressures [2]. Management has signaled a pending CEO transition and highlighted the importance of cost reduction and operational improvement plans.

Investors and financial professionals should keep an eye on the stabilization or improvement in Laboratory Solutions revenue trends, margin development in both major segments, progress in Avantor's cost-saving initiatives, and any updates on tariff-related risks or mitigation measures. Additionally, the upcoming CEO transition will be a key factor to watch, as life sciences veteran Emmanuel Ligner is set to take the helm on August 18, 2025.

References:
[1] https://seekingalpha.com/news/4482965-engine-capital-builds-3-stake-in-avantor-to-press-for-strategic-changes-sale---report
[2] https://www.nasdaq.com/articles/avantor-q2-revenue-tops-estimates
[3] https://www.investing.com/news/stock-market-news/activist-investor-engine-capital-to-push-avantor-to-sell-itself-wsj-4181747